Skip to main content

Table 1 Comparison of clinical and pathologic characteristics of breast cancer patients according to the phospho-p90RSK expression

From: Phosphorylation of p90RSK is associated with increased response to neoadjuvant chemotherapy in ER-positive breast cancer

   Low P90RSK High P90RSK  
Mean age   55.3 (±10.4) 48.3 (±11.9) 0.004
Initial tumor size (cm)   5.1 (±2.3) 5.2 (2.4) 0.734
cT stage cT1-2 18 (55%) 38 (48%) 0.339
  cT3-4 15 (45%) 41 (52%)  
cN stage cN0-1 21 (64%) 40 (51%) 0.149
  cN2-3 12 (36%) 39 (49%)  
pCR pCR no 29 (88%) 72 (91%) 0.414
  pCR yes 4 (12%) 7 (9%)  
Estrogen receptor ER negative 18 (55%) 42 (53%) 0.530
  ER positive 15 (45%) 37 (47%)  
Progesterone receptor PR negative 10 (67%) 36 (64%) 0.560
  PR positive 5 (33%) 20 (36%)  
HER2 overexpression HER2 negative 10 (67%) 39 (70%) 0.527
  HER2 positive 5 (33%) 17 (30%)